← All countries · Americas
88%
MCV1
2025 · WHO/UNICEF estimate
83%
DTP3
2025 · WHO/UNICEF estimate
86%
IPV complete
2025 · WHO/UNICEF estimate
83%
HepB3
2025 · WHO/UNICEF estimate
44
Measles cases
2025 reported
1
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 87%2025 · WHO/UNICEF estimate | 87.2% | A · strong | |
| DTP1First dose of diphtheria-tetanus-pertussis | 89%2025 · WHO/UNICEF estimate | 89.3% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 83%2025 · WHO/UNICEF estimate | 83.1% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 89%2025 · WHO/UNICEF estimate | 89.3% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 86%2025 · WHO/UNICEF estimate | 86.2% | C · weak | |
| MCV1First dose of measles-containing vaccine | 88%2025 · WHO/UNICEF estimate | 87.9% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 91%2025 · WHO/UNICEF estimate | 90.9% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 88%2025 · WHO/UNICEF estimate | 87.9% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 83%2025 · WHO/UNICEF estimate | 83.1% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 78%2025 · WHO/UNICEF estimate | 78.4% | B · good | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 83%2025 · WHO/UNICEF estimate | 83.1% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 83.0%2025 · Administrative (country-reported) | 83.0% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 75%2025 · WHO/UNICEF estimate | 74.6% | C · weak | |
| RotaCRotavirus vaccine, complete series | 17%2025 · WHO/UNICEF estimate | 17.4% | too few points | C · weak |
| Yellow feverYellow fever vaccine (countries at risk) | 72.7%2015 · Administrative (country-reported) | 72.7% | D · poor | |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | D · poor |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 95%2024 · WHO/UNICEF estimate | 87.2% | B · good | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 69%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 69%2025 · WHO/UNICEF estimate | — | C · weak | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 55%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 442025 | 104per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 102025 | 23.6per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 12025 | 2.4per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 12025 | 2.4per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02025 | 0per 1,000,000 <15 population | C · weak | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02006 | 0per 1,000,000 total population | too few points | no data |
| Invasive meningococcal disease all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (65 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | Children below age 1 year |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Adults with chronic conditions, older adults with chronic conditions | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 1 | M2 | Risk group(s) | Recommended for children with contraindication to pertussis containing vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 2 | M4 | Risk group(s) | Recommended for children with contraindication to pertussis containing vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 3 | M6 | Risk group(s) | Recommended for children with contraindication to pertussis containing vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 4 | M18 | Risk group(s) | Recommended for children with contraindication to pertussis containing vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 5 | Y4 | Risk group(s) | Recommended for children with contraindication to pertussis containing vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 6 | Y12 | Risk group(s) | Recommended for children with contraindication to pertussis containing vaccine |
| DTWPDTwP (Whole cell) vaccine | 5 | Y4 | General/routine | Children 48 months |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 1 | M2 | General/routine | children 2 months to 18 months, changed from Pentavalent to Hexavalent July 2025 |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 2 | M4 | General/routine | children 2 months to 18 months, changed from Pentavalent to Hexavalent July 2025 |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 3 | M6 | General/routine | children 2 months to 18 months, changed from Pentavalent to Hexavalent July 2025 |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 4 | M18 | General/routine | children 2 months to 18 months, changed from Pentavalent to Hexavalent July 2025 |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Adults | Health Care and other front line workers, and given to adults on request or without documentation of Hep B as a child |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers | Health Care and other front line workers, and given to adults on request or without documentation of Hep B as a child |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Risk group(s) | Health Care and other front line workers, and given to adults on request or without documentation of Hep B as a child |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Adults | Health Care and other front line workers, and given to adults on request or without documentation of Hep B as a child |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Health workers | Health Care and other front line workers, and given to adults on request or without documentation of Hep B as a child |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Risk group(s) | Health Care and other front line workers, and given to adults on request or without documentation of Hep B as a child |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Adults | Health Care and other front line workers, and given to adults on request or without documentation of Hep B as a child |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Health workers | Health Care and other front line workers, and given to adults on request or without documentation of Hep B as a child |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Risk group(s) | Health Care and other front line workers, and given to adults on request or without documentation of Hep B as a child |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | new borns. Hep B Paediatric dose is given at birth at hospital within 24 hours after birth (if not administered then can be given before child is two months) |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y9 | HPV administered to females and males | Only one dose is administered since May 2023, to school children in Std 4 class. males and females 9-14 years. School based program but also administered in clinic settings as necessary |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons 65+ |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | Children 12 and 18 months |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M18 | General/routine | Children 12 and 18 months |
| MRMR (Measles and rubella) vaccine | 1 | >=Y11 | Risk group(s) | Persons over 10 years who have not received MMR vaccine, started in 2025 |
| MRMR (Measles and rubella) vaccine | 2 | >=Y11 | Risk group(s) | Persons over 10 years who have not received MMR vaccine, started in 2025 |
| OPVOPV (Oral polio vaccine) | 3 | M6 | General/routine | Children 6 months, 18 months and 4 years |
| OPVOPV (Oral polio vaccine) | 4 | M18 | General/routine | Children 6 months, 18 months and 4 years |
| OPVOPV (Oral polio vaccine) | 5 | Y4 | General/routine | Children 6 months, 18 months and 4 years |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | <Y5 | Catch-up children | 2M, 4M, 6M. Vaccinated in campaignstarted in December 2023, catch up for children under 5 years |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | M2 | General/routine | 2M, 4M, 6M. Vaccinated in campaignstarted in December 2023, catch up for children under 5 years |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 2 | M4 | General/routine | 2M, 4M, 6M. Vaccinated in campaignstarted in December 2023, catch up for children under 5 years |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 3 | M6 | General/routine | 2M, 4M, 6M. Vaccinated in campaignstarted in December 2023, catch up for children under 5 years |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | Adults | Children above 5 years and adults. Started 2025 | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | Risk group(s) | Children above 5 years and adults. Started 2025 | |
| RABIESRabies vaccine | 1 | 1st contact | Risk group(s) | Environmental health program to exposed individuals |
| RABIESRabies vaccine | 2 | +D3 | Risk group(s) | Environmental health program to exposed individuals |
| RABIESRabies vaccine | 3 | +D7 | Risk group(s) | Environmental health program to exposed individuals |
| RABIESRabies vaccine | 4 | +D14 | Risk group(s) | Environmental health program to exposed individuals |
| RABIESRabies vaccine | 5 | +D28 | Risk group(s) | Environmental health program to exposed individuals |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | <Y2 | Catch-up children | Children 2, 4, 6 months, started in August 2025, catch up for those under 2 years |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | M2 | General/routine | Children 2, 4, 6 months, started in August 2025, catch up for those under 2 years |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M4 | General/routine | Children 2, 4, 6 months, started in August 2025, catch up for those under 2 years |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M6 | General/routine | Children 2, 4, 6 months, started in August 2025, catch up for those under 2 years |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Pregnant women | Pregnant without proof of previous vaccination are given 2 doses |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | Pregnant women | Pregnant without proof of previous vaccination are given 2 doses | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y12 | General/routine | Children in Std 6 (age 12) given a booster dose |
| VITAMINAVitamin A supplements | 1 | M6 | General/routine | |
| VITAMINAVitamin A supplements | 2 | M12 | General/routine | |
| VITAMINAVitamin A supplements | 3 | M18 | General/routine | |
| VITAMINAVitamin A supplements | 4 | M24 | General/routine | |
| VITAMINAVitamin A supplements | 5 | M30 | General/routine | |
| VITAMINAVitamin A supplements | 6 | M36 | General/routine | |
| YFYF (Yellow fever) vaccine | 1 | 1st contact | Travellers | Travellers to countries endemic to YF from age 9 months (1dose) |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.